Know Cancer

or
forgot password

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)


Phase 3
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)


During follow-up, it was determined that there was one additional patient on placebo that
was still receiving treatment as of 06 APR 2010 and therefore 10 patients' data are reported
in the current CSR addendum, 6 in the sorafenib + GC group and 4 in the placebo + GC group,
and as before all in the ITT (non-squamous) population.


Inclusion Criteria:



- Age > 18 years old

- Stage IIIB (with cytologically confirmed malignant pleural or pericardial effusion)
or Stage IV histological or cytological confirmation of NSCLC of non-squamous cell
carcinoma subtype. (thoracentesis or pericardiocentesis is not necessary if a biopsy
of the original tumor is available to confirm diagnosis of NSCLC).

- Patients with at least one measurable lesion. Lesions must be measured by CT-scan or
MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid
Tumors (RECIST, see Appendix 10.3)

- Life expectancy of at least 12 weeks

- Adequate bone marrow, liver and renal function as assessed by the following
laboratory requirements to be conducted within 7 days prior to start of first dose:

- Hemoglobin >/= 9.0 g/dl (>/= 5.6 mmol/l)

- Absolute neutrophil count (ANC) >/= 1,500/mm3

- Platelet count >/= 100,000/┬Ál

- Total bilirubin
- Alanine transaminase (ALT) and Aspartate transaminase (AST) normal ( cancer)

- Alkaline Phosphatase
- PT-INR (Prothrombin Time - International Normalized Ratio) (international normalized
ratio of PT) /PTT (Partial Thromboplastin Time) < 1.5 x upper limit of normal

- Serum Creatinine Clearance >/= 70ml/min

- Ability to understand and the willingness to sign a written informed consent. A
signed informed consent must be obtained prior to performing any study specific
procedures.

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Exclusion Criteria:

- Excluded medical conditions:

- Cardiac disease: Congestive heart failure > class II NYHA (New York Heart
Association). Patients must not have unstable angina (anginal symptoms at rest)
or active coronary artery disease (CAD), or myocardial infarction within the
past 6 months

- Cardiac arrhythmias requiring anti-arrhythmic therapy

- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or
diastolic pressure > 90 mmHg, despite optimal medical management.

- History of HIV (Human immunodeficiency virus) infection or chronic hepatitis B
or C

- Active clinically serious infections (> grade 2 NCI-CTCAE (National Cancer
Institute Common Terminology Criteria for Adverse Events) version 3.0)

- Patients with seizure disorder requiring medication (such as steroids or
anti-epileptics)

- Known brain metastasis. Patients with neurological symptoms should undergo a CT
scan/MRI of the brain to exclude brain metastasis.

- History of organ allograft

- Patients with evidence or history of bleeding diathesis or coagulopathy

- Patients undergoing renal dialysis

- Cancer other than NSCLC within 5 years prior to start of study treatment EXCEPT
cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder
tumors [Ta (Noninvasive tumor), Tis (Carcinoma in situ) & T1 (Tumor invades
lamina propria)]

- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or
diastolic pressure > 90 mmHg, despite optimal medical management.

- Thrombotic or embolic events such as cerebrovascular accident including
transient ischemic attacks within the past 6 months

- Pulmonary hemorrhage/bleeding event > Common Terminology Criteria for Adverse
Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug

- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose
of study drug

- Serious, non-healing wound, ulcer, or bone fracture

- Uncorrected dehydration

- Pregnant or breast-feeding patients. Women of childbearing potential must have
a negative pregnancy test performed within 7 days of the start of treatment.
Both men and women enrolled in this trial must use adequate birth control
measures during the course of the trial. The definition of effective
contraception will be based on the judgment of the principal investigator or a
designated associate.

- Substance abuse, medical, psychological or social conditions that may interfere
with the patient's participation in the study or evaluation of the study results

- Known or suspected allergy to the investigational agent or any agent given in
association with this trial

- Any condition that is unstable or could jeopardize the safety of the patient and
their compliance in the study

- Patients unable to swallow oral medications

- Any malabsorption condition

- Patients with a hearing impairment (FOR GERMANY ONLY)

- NSCLC patients with squamous cell carcinoma diagnosis documented either by
cytology or biopsy.

- Excluded therapies and medications, previous and concomitant:

- Any prior systemic anticancer therapy including cytotoxic therapy, targeted
agents, experimental therapy, adjuvant, or neo-adjuvant therapy for NSCLC

- Concomitant use of nephrotoxic drugs, ototoxic drugs, anticonvulsant, anti-gout
treatment

- Radiotherapy during study or within 3 weeks of start of study drug. (Palliative
radiotherapy will be allowed as described in the Prior and Concomitant Therapy
section)

- Radiotherapy during study or within 4 weeks of start of study drug. (Palliative
radiotherapy will be allowed as described in the Prior and Concomitant Therapy
section) (FOR FRANCE ONLY)

- Major surgery, open biopsy or significant traumatic injury within 4 weeks of
first dose of study drug (bronchoscopy is allowed)

- Granulocyte colony stimulating factor (GCSF) or Granulocyte macrophage colony
stimulating factor (GMCSF), within 3 weeks of study entry (these growth factors
may be used during the study thereafter).

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Survival (OS) in the ITT (Non-squamous) Population

Outcome Description:

Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Patients still alive at the time of analysis were censored at their last date of last contact.

Outcome Time Frame:

from randomization of the first patient until 38 months or date of death of any cause whichever came first

Safety Issue:

No

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

12006

NCT ID:

NCT00449033

Start Date:

February 2007

Completion Date:

June 2011

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Non-Small Cell Lung Cancer (NSCLC)
  • Cancer
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location